Daily Newsletter

22 June 2023

Daily Newsletter

22 June 2023

Xeris Biopharma dosing patients in hypothyroidism drug trial

The study will include a titration period of two to eight weeks, screening and a four-week maintenance period.

June 22 2023

US-based pharmaceutical company Xeris Biopharma has dosed the first participant in a Phase II clinical trial of subcutaneous (SC) XP-8121 injection to treat adults with hypothyroidism.

The trial will assess the tolerability and safety of XP-8121 (levothyroxine sodium) in patients with hypothyroidism, who will be subcutaneously injected with the therapy once a week.

It will also determine a target dose conversion factor from stably dosed oral levothyroxine to XP-8121.

The study is being carried out as a self-controlled, non-randomised, multi-centre, single-arm, open-label trial.

It will include a titration period of two to eight weeks, screening and a four-week maintenance period.

During the maintenance period, a subset of patients will undergo a pharmacokinetic sub-study.

Xeris global development and medical affairs senior vice-president Kenneth Johnson said: “We are excited to have dosed the first participant in our Phase II dose-finding study of XP-8121 and are actively recruiting additional participants that meet the eligibility criteria.

“We anticipate a lengthy recruitment period as enrolling stably dosed patients with normal TSH on oral levothyroxine is challenging and speaks further to the need of developing a once-weekly SC injection.

“Depending upon enrollment rates, we anticipate completing the study in the first half of 2024.”

Safety data and the derived average once-weekly dose of XP-8121 from this study will allow Xeris to begin a Phase III programme.

Xeris chairman and CEO Paul Edick said: “Oral levothyroxine is one of the most prescribed medicines in the United States, generating more than 100 million prescriptions a year.

“We believe that our novel SC formulation of levothyroxine has the potential to provide patients with a once-weekly dosing, thereby potentially improving treatment adherence, as well as bypassing the gastrointestinal (GI) tract.”

Xeris is also engaged in developing formulations for treating endogenous Cushing’s syndrome, primary periodic paralysis and severe hypoglycaemia.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close